Journal of Neuro-Oncology最新文献

{"title":"Summary of the collection on 'immunotherapy in pediatric brain tumors-an update'.","authors":"Soumen Khatua, Eric Bouffet","doi":"10.1007/s11060-025-05191-x","DOIUrl":"10.1007/s11060-025-05191-x","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1467-1468"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of hypertension timing for survival in glioblastoma patients receiving bevacizumab: a retrospective single centre analysis.","authors":"Irfan Kesumayadi, Atsushi Kambe, Hidefumi Amisaki, Tomohiro Hosoya, Makoto Sakamoto, Masamichi Kurosaki","doi":"10.1007/s11060-025-05209-4","DOIUrl":"10.1007/s11060-025-05209-4","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension, the most common adverse events associated with bevacizumab (BEV) treatment, has been proposed as a potential biomarker of treatment response in glioblastoma (GBM) patients. This study aimed to evaluate whether the timing of hypertension serves as a prognostic value in GBM patients.</p><p><strong>Methods: </strong>This retrospective study consisting of 56 GBM patients treated with initial BEV between 2013 and 2024. Blood pressure was monitored peri-infusion of BEV (before and 60 min after). Patients were grouped into normotension, pre-existing hypertension (before first BEV infusion), and BEV-induced hypertension, further classified as early new-onset (≤ 3 cycles) or late-onset (> 3 cycles). Overall survival (OS) was assessed using the Kaplan-Meier method.</p><p><strong>Results: </strong>Fifteen (36.6%) patients had pre-existing hypertension, while 26 (63.4%) were normotensive at baseline. Among the normotensive patients, twelve (46.1%) developed early new-onset hypertension, and 13 (50%) developed late-onset hypertension. Patients with pre-existing hypertension demonstrated significantly longer median OS compared to normotensive patients (32 vs. 22 months, p = 0.043). Early new-onset hypertension was also associated with improved OS compared to patients who remained normotensive after three cycles (25 vs. 16 months, p = 0.003). Additionally, patients with pre-existing and early new-onset hypertension showed longer OS compared to those with late-onset hypertension (25 vs. 14 months, p = 0.002).</p><p><strong>Conclusion: </strong>Monitoring blood pressure during peri-infusion of BEV could be useful in predicting treatment response for GBM patients. Pre-existing or early new-onset hypertension is associated with improved survival, suggesting that timing of hypertension has a potential role as a biomarker for BEV efficacy.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1425-1433"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Community-level social capital and postoperative outcomes following intracranial tumor surgery: an exploration of the Social Capital Atlas in neurosurgical oncology.","authors":"Sachiv Chakravarti, Atharv Oak, Linda Tang, Yuncong Mao, Jordan Vanleuven, Julian Gendreau, A Karim Ahmed, Jordina Rincon-Torroella, Christopher Jackson, Gary Gallia, Chetan Bettegowda, Jon Weingart, Debraj Mukherjee","doi":"10.1007/s11060-025-05207-6","DOIUrl":"10.1007/s11060-025-05207-6","url":null,"abstract":"<p><strong>Background and objectives: </strong>Explore whether community social capital measures (system of resources available to individuals through community engagement) are related to surgical outcomes among intracranial tumor patients.</p><p><strong>Methods: </strong>Adults who underwent resection at a single medical center for intracranial tumor was identified and their zip codes were matched to three variables derived from the Social Capital Atlas: economic connectedness, volunteering rate, and civic organizations. The economic connectedness score quantifies the degree to which low-income and high-income community members are friends with each other, the volunteering rate is defined as the proportion of a given community engaged in community organizations and the civic organization score is defined as the number of local civic organizations within a given community. Chi-square and Mann-Whitney U tests were used to compare demographic and clinical characteristics between patients who were in the > 75 and < 25 percentiles of each social capital measure. Multivariate logistic regression was used to assess the effect of social capital measures on postoperative outcomes.</p><p><strong>Results: </strong>A total of 2,373 patients were included in the present study. A majority were white (70.7%) and female (53%); the most common diagnosis was meningioma (24.0%). On multivariate analysis, for every additional civic organization in a patient's community per 1,000 community members, odds of extended hospital LOS, high hospital costs, and nonroutine discharge disposition was reduced by 60.3% (p = 0.006), 63.4% (p = 0.008) and 68.9% (p = 0.013) respectively. Further, for each point increase in community economic connectedness score and each percent increase in community volunteering rate, odds of extended LOS were reduced by 13.1% (p = 0.036) and 23.0% (p = 0.011), respectively.</p><p><strong>Conclusion: </strong>Intracranial tumor patients with low social capital are at-risk for poor high-value care outcomes that may be amenable to case management or social work intervention.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1455-1463"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry.","authors":"David Wasilewski, Chiara Eitner, Rober Ates, Selin Murad, Zoe Shaked, Julia Alexandra Steinle, Andreas Wetzel-Yalelis, Tarik Alp Sargut, Judith Rösler, Majd Abdulhamid Samman, Peter Truckenmüller, Robert Mertens, Daniel Kroneberg, Alexander Kowski, Helena Radbruch, David Capper, Felix Ehret, Siyer Roohani, Nikolaj Frost, Jawed Nawabi, Julia Onken, Maximilian Schlaak, Jens-Uwe Blohmer, Uwe Pelzer, Ulrich Keller, Jalid Sehouli, Peter Vajkoczy, Ulrich Keilholz, Martin Misch","doi":"10.1007/s11060-025-04937-x","DOIUrl":"10.1007/s11060-025-04937-x","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Leptomeningeal disease (LMD) involves disseminating cancer cells to the leptomeninges and cerebrospinal fluid. The impact of intracranial parenchymal brain metastases and extracranial disease burden at LMD diagnosis remains unclear. This study evaluates these factors alongside local and systemic therapies before and after LMD diagnosis.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 188 patients diagnosed with LMD between 2011 and 2024. Data on demographics, imaging findings, and treatments were collected. Kaplan-Meier estimates were used for survival analysis, and independent prognostic factors were identified using a backward-stepwise Cox regression model.</p><p><strong>Results: </strong>Primary cancers included breast cancer (34.0%), non-small cell lung cancer (22.3%), and melanoma (14.4%). LMD was diagnosed via MRI in 56.4% of cases, cerebrospinal fluid (CSF) cytology in 2.7%, and both in 41.0%. Median overall survival was 2.8 months [95% CI: 2.4 - 3.7]. Independent prognostic factors for improved survival included male sex (HR: 0.61 [95% CI: 0.40 - 0.93], p = 0.020), absence of hydrocephalus at LMD diagnosis (HR: 0.42 [95% CI: 0.22 - 0.79], p = 0.007), and targeted therapy post-diagnosis (HR: 0.33 [95% CI: 0.20 - 0.55], p < 0.001). Two or more lines of systemic therapy before LMD diagnosis increased mortality risk (HR: 1.73 [95% CI: 1.16 - 2.59], p = 0.007). Lack of CNS parenchymal disease at LMD diagnosis also increased risk (HR: 0.51 [95% CI: 0.30 - 0.89], p = 0.017). Pre-diagnosis radiation therapy showed no survival benefit, while post-diagnosis radiation improved outcomes (HR: 0.47 [95% CI: 0.32 - 0.70], p < 0.001).</p><p><strong>Conclusion: </strong>Absence of hydrocephalus and use of targeted therapy post-diagnosis are favorable prognostic factors, while extensive prior systemic therapy and CNS parenchymal disease worsen outcomes. Tailored therapies addressing intracranial disease are crucial for improving survival in LMD patients.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"943-965"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative hydrocephalus in patients with infratentorial brain metastases may be influenced by preoperative treatment: a single-center cohort study.","authors":"Luisa Mona Kraus, Maria Goldberg, Eugen Ursu, Kayra Demirbag, Simon Paul Backhaus, Ghaith Altawalbeh, Denise Bernhardt, Chiara Negwer, Stephanie Combs, Bernhard Meyer, Arthur Wagner","doi":"10.1007/s11060-025-05125-7","DOIUrl":"10.1007/s11060-025-05125-7","url":null,"abstract":"<p><strong>Purpose: </strong>Infratentorial brain metastases (BM), particularly those causing obstruction of the fourth ventricle, are associated with a significant risk of postoperative hydrocephalus. This complication remains poorly understood, especially regarding its predictors beyond mechanical obstruction. This study aims to identify clinical predictors of postoperative hydrocephalus in patients undergoing surgery for infratentorial BM.</p><p><strong>Methods: </strong>We performed a single-center retrospective analysis of 235 adult patients surgically treated for infratentorial BM between 2009 and 2025. Patients with leptomeningeal disease were excluded. Pre- and postoperative hydrocephalus were defined based on imaging and clinical criteria. Logistic regression and multivariate modeling were used to evaluate predictors, including clinical presentation, treatment history, and imaging features.</p><p><strong>Results: </strong>Postoperative hydrocephalus occurred in 18.45% of patients. Breast cancer patients exhibited the highest incidence (30.61%), significantly more than those with lung cancer (15.66%, p = 0.042). Preoperative hydrocephalus (p = 0.005), and prior chemotherapy (p = 0.001) or radiotherapy (p = 0.004) were significantly associated with postoperative hydrocephalus. Imaging variables, including tumor volume or proximity to the fourth ventricle, were not predictive. Multivariate regression confirmed preoperative hydrocephalus, and systemic treatment as independent risk factors.</p><p><strong>Conclusion: </strong>Postoperative hydrocephalus in infratentorial BM is influenced not only by mechanical factors but also by preoperative clinical and therapeutic variables. Breast cancer patients, particularly those who received prior systemic or local therapy, are at higher risk. These findings suggest the need for individualized risk assessment and raise the question of whether prophylactic interventions could mitigate complications and treatment delays in high-risk cohorts.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1391-1399"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term tumour control of cystic and solid vestibular schwannoma treated with LINAC-based stereotactic radiosurgery: a retrospective analysis.","authors":"Aaron Jin, Daniel Roos, Adrian Esterman, Sandy Patel, Peter Gorayski, Frank Saran, Ramkumar Govindaraj","doi":"10.1007/s11060-025-05199-3","DOIUrl":"10.1007/s11060-025-05199-3","url":null,"abstract":"<p><strong>Purpose: </strong>The implications of intratumoural cystic change on management and treatment outcomes in vestibular schwannoma (VS) remain uncertain. This retrospective analysis aims to compare the treatment outcomes of solid and cystic tumours treated with linear accelerator (LINAC)-based stereotactic radiosurgery (SRS).</p><p><strong>Methods: </strong>Sixty-eight patients were analysed including 22 with cystic tumours. All received a marginal dose of 12 Gy to the 80% isodose line (range: 70-90%) delivered in a single fraction. Local progression was defined as a maximum linear dimension (MLD) enlargement of > 2 mm persisting for over 2 years, pseudoprogression as an MLD enlargement of > 2 mm within the first 2 years followed by stability or reduction.</p><p><strong>Results: </strong>With an average follow-up of 92.2 months, crude tumour control rates were similar: 95.5% for cystic and 93.5% for solid tumours. Pseudoprogression occurred in 7 patients (10.3%), 2 with solid (4.3%) and 5 with cystic VS (22.7%). The mean MLD reduction was 4.2 mm for solid tumours and 5.0 mm for cystic tumours (p = 0.51). Only pretreatment size correlated with the percentage reduction in tumour diameter (p = 0.025). Although a higher proportion of cystic tumours demonstrated at least a 10%, 20%, and 30% size reduction compared to solid tumours, none of these differences were statistically significant.</p><p><strong>Conclusion: </strong>LINAC-based SRS achieves similar tumour control for both cystic and solid VS. Despite cystic tumours being typically of higher Koos grade, they may demonstrate numerically greater reduction after SRS. Future studies should aim to standardise the criteria for classifying cystic tumours.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1155-1161"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world experience with selumetinib in children with neurofibromatosis type 1: a multicentric retrospective study.","authors":"Claudia Santoro, Mariachiara Servedio, Maria Cristina Diana, Irene Russo, Elena Arkhangelskaya, Gianluca Piccolo, Andrea Santangelo, Angela Mastronuzzi, Antonella Cacchione, May El Hachem, Carmela Russo, Mario Cirillo, Ilaria Cecconi, Antonio Grasso, Mariateresa Loiotine, Nicola Santoro, Mariachiara Resta, Carmela De Meco, Consolata Soddu, Eugenia Spreafico, Bartolomeo Rossi, Chiara Fossati, Chiara Leoni, Silverio Perrotta, Teresa Perillo","doi":"10.1007/s11060-025-05197-5","DOIUrl":"10.1007/s11060-025-05197-5","url":null,"abstract":"<p><strong>Purpose: </strong>Selumetinib is a MEK inhibitor indicated for pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic inoperable plexiform neurofibromas (PNs).</p><p><strong>Methods: </strong>This retrospective study collected data from 70 patients (aged 3 - 18 years) with NF1 and symptomatic inoperable PNs treated with selumetinib as part of compassionate use at 11 Italian centers between October 2018 and October 2024. Assessments included the clinical benefit rate (CBR) after 24 months and at the last observation. Major response (MR) was defined as a ≥ 50% reduction from baseline in tumor volume. Adverse events (AEs), patient-reported pain and quality of life (QoL), and Eastern Cooperative Oncology Group performance status (ECOG PS), were also evaluated.</p><p><strong>Results: </strong>Of 45/70 patients with available natural history data at C0, 33/45 (73.3%) had progressive disease (PD). Radiological evaluation at C6 in 17/33 patients showed 16 (94.1%) had stable disease (SD) or partial response (PR). 52/58 patients (91.5%) had SD or PR/MR at C12; final response at last radiological follow-up was PD (7.7%), SD (42.3%), PR (30.8%) and MR (19.2%). CBR was 83.3% (24/70) at C24 and 91.5% (43/47) at last radiological follow-up. Selumetinib significantly reduced pain perception and improved QoL and ECOG PS. The type of response at C6 seems to predict response at C12 and at last observation. Adverse events were generally mild (78% grade ≤ 2).</p><p><strong>Conclusion: </strong>Our findings suggest that the response after 6 and 12 selumetinib cycles may predict long-term outcomes, providing clinicians with an early indicator for therapeutic decision-making.</p><p><strong>Trial registration number: </strong>Not applicable.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1027-1037"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT).","authors":"Mirjam Renovanz, Melina Hippler, Robert Kuchen, Lorenz Doerner, David Rieger, Joachim P Steinbach, Michael W Ronellenfitsch, Martin Voss, Almuth F Kessler, Vera Nickl, Martin Misch, Julia Sophie Onken, Marion Rapp, Minou Nadji-Ohl, Marcus Mehlitz, Jürgen Meixensberger, Michael Karl Fehrenbach, Naureen Keric, Florian Ringel, Jan Coburger, Carolin Weiß Lucas, Jens Wehinger, Friederike Schmidt-Graf, Jens Gempt, Marcos Tatagiba, Ghazaleh Tabatabai, Melanie Schranz, Susanne Singer","doi":"10.1007/s11060-025-05223-6","DOIUrl":"10.1007/s11060-025-05223-6","url":null,"abstract":"<p><strong>Purpose: </strong>Patients diagnosed with high-grade gliomas (HGG) often experience substantial psychosocial dis-tress. However, due to neurological and neurocognitive deficits its assessment remains challenging, and needs remain unmet. We compared a novel face-to-face assessment during doctor-patient conversations with questionnaire-based screening.</p><p><strong>Methods: </strong>In this multicenter, two-arm cluster-randomized study involving 13 centers patients in the interven-tion group (IG) were screened for distress via physician-patient conversations, while the control group (CG) completed the Distress Thermometer. Primary outcome was the proportion of patients with poor emotional functioning (measured with the EORTC Quality of Life Questionnaire) who received specialized psychosocial care (PC) within 3 months. Data were collected via patient and physician reports and medical records. Analysis employed mixed models logistic regression.</p><p><strong>Results: </strong>In total, 763 patients were enrolled at baseline, and 506 completed the follow-up. The emotional functioning was poor in 302/506 (59.7%). The frequency of patients reporting PC utilization was comparable between groups (IG 93/168, 55.4% vs. CG 87/134, 64.9%, odds ratio (OR) =0.67, 95% confidence interval (CI)=0.40-1.11, p=0.115). Likewise, the provision of information about special-ized psycho-oncological care was similar (IG 112/168, 66.7% vs. CG 94/134, 70.1%, OR=0.95, 95%CI=0.39-2.29, p=0.904).</p><p><strong>Conclusion: </strong>Physician-led, face-to-face distress screening was not superior to questionnaire-based screening in facilitating psychosocial care referrals. Nonetheless, it represents a feasible and patient-centered alternative, particularly for patients with high-grade gliomas suffering from neurocognitive or func-tional deficits.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"967-977"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TMEM164 enhances radioresistance of GBM cells by inhibiting the FASN-NADPH-ROS axis.","authors":"Zhaoyan Jiang, Xiaoya Jin, Hetian Xue, Jialing Zhang, Liang Zeng, Yuchuan Zhou, Yan Pan, Jianghong Zhang, Chunlin Shao","doi":"10.1007/s11060-025-05216-5","DOIUrl":"10.1007/s11060-025-05216-5","url":null,"abstract":"<p><strong>Purpose: </strong>Glioblastoma multiforme (GBM), one of the most aggressive primary brain malignancies, remains a major therapeutic challenge in contemporary neuro-oncology. Radiotherapy, an essential component of current standard therapeutic protocol, still has persistently poor clinical efficacy in the intrinsic radioresistance of GBM. Therefore, elucidating the underlying mechanisms of radioresistance is critical for optimizing therapeutic outcomes in GBM patients.</p><p><strong>Methods: </strong>Radioresistant GBM cell lines U251R were established by irradiating U251 cells with fractionated dose of 60 Gy in total. RNA-seq and TMT assays were applied, combined with GEO, KEGG and other databases to analyze the role of TMEM164 in regulating the radiosensitivity of GBM cells. Pharmacological inhibition of cell death pathways was employed to identify the predominant cell death mechanism influencing TMEM164-mediated radioresistance in GBM cells. The intracellular levels of NADPH, lipid droplet and ROS were detected after radiation to assess the effect of TMEM164 on lipid metabolism. The effect of TMEM164 on necroptosis through FASN-NADPH-ROS axis was verified by rescue experiments.</p><p><strong>Results: </strong>Through bioinformatics analysis, TMEM164 was identified as a key gene regulating GBM cells' radiosensitivity. Knockdown of TMEM164 significantly increased necroptosis in U251R and T98G cells. Integrated enrichment analysis of RNA-seq and TMT data revealed that FASN interacted with TMEM164. Excessive NADPH consumption led to intracellular ROS accumulation, thereby increasing radiosensitivity in GBM cells.</p><p><strong>Conclusions: </strong>Our findings indicated that TMEM164 might serve as a critical biological target of GBM cells radioresistance, providing a novel theoretical basis for GBM radiotherapy.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1011-1026"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: \"Anatomical distribution and prognostic heterogeneity in glioma: unique clinical features of occipital glioblastoma\".","authors":"Ichiyo Shibahara, Toshihiro Kumabe","doi":"10.1007/s11060-025-05226-3","DOIUrl":"10.1007/s11060-025-05226-3","url":null,"abstract":"<p><p>Strategy for occipital isolation by disconnecting convergent white matter fibers. A region of interest (ROI, yellow sphere) was placed in the occipital lobe, and tractography shows streamlines from the ROI. Two major bundles course along the bottom of the parietooccipital fissure (POF) and the trigone of the lateral ventricle. The anterior resection border (light-blue line) is defined by a line connecting the bottom of the POF to the trigone; the lateral resection border (green line) corresponds to the trigonal width measured from the midline. blue line and triangle, trigone of the lateral ventricle; red line and arrow, POF; yellow circle, convergence of fibers along the ventricular wall.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1471-1472"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}